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Abstract
In the event of a terrorist-mediated attack in the United States using radiological or improvised nuclear weapons, it is
expected that hundreds of thousands of people could be exposed to life-threatening levels of ionizing radiation. We have
recently shown that genome-wide expression analysis of the peripheral blood (PB) can generate gene expression profiles
that can predict radiation exposure and distinguish the dose level of exposure following total body irradiation (TBI).
However, in the event a radiation-mass casualty scenario, many victims will have heterogeneous exposure due to partial
shielding and it is unknown whether PB gene expression profiles would be useful in predicting the status of partially
irradiated individuals. Here, we identified gene expression profiles in the PB that were characteristic of anterior hemibody-,
posterior hemibody- and single limb-irradiation at 0.5 Gy, 2 Gy and 10 Gy in C57Bl6 mice. These PB signatures predicted the
radiation status of partially irradiated mice with a high level of accuracy (range 79–100%) compared to non-irradiated mice.
Interestingly, PB signatures of partial body irradiation were poorly predictive of radiation status by site of injury (range 16–
43%), suggesting that the PB molecular response to partial body irradiation was anatomic site specific. Importantly, PB gene
signatures generated from TBI-treated mice failed completely to predict the radiation status of partially irradiated animals or
non-irradiated controls. These data demonstrate that partial body irradiation, even to a single limb, generates a
characteristic PB signature of radiation injury and thus may necessitate the use of multiple signatures, both partial body and
total body, to accurately assess the status of an individual exposed to radiation.
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Introduction
In the event of a terrorist-driven detonation of an improvised
nuclear device (IND) in a populated U.S. city, it is expected that
hundreds of thousands of people could be exposed to ionizing
radiation, with even larger numbers fearful that they have been
exposed [1–4]. Over the past 5 years, U.S. federal, state and local
governments and leading medical societies have spearheaded
efforts to organize the medical response to such an event and
highly considered, well-conceived therapeutic guidelines have
been made publicly available for health care providers to have
‘‘just in time’ algorithms as to how to treat radiation victims should
an event occur [5,6]. However, the successful implementation of
any large scale medical response for a mass casualty radiation
event will depend upon the availability and utility of diagnostic
tests to determine radiation exposure status and dose of exposure
among victims and the availability of therapeutics that can be
administered to mitigate radiation damage to vital organ systems
[2–4,7,8].
We have applied genome-wide analytical methods and high-
throughput computational tools to determine whether ‘‘signa-
tures’’ of radiation injury can be identified in the peripheral blood
(PB) of mice and humans following exposure to several dose levels
of gamma irradiation [9]. Utilizing a binary regression analysis,
patterns of gene expression (50–100 genes) were identified in the
PB of mice that were capable of predicting radiation status and
distinguishing the dose level of exposure between non-irradiated,
0.5 Gy-, 2 Gy- and 10 Gy-irradiated animals with accuracy of
96% [9]. We subsequently applied this same approach to
predicting the radiation status of humans who received total body
irradiation (TBI) prior to stem cell transplantation as compared to
non-irradiated patients and healthy human controls and found
that a PB signature of 25 genes was capable of predicting the
radiation status of humans with an overall accuracy of 95% [10].
Taken together, these studies confirmed the power of PB gene
expression profiles or ‘‘metagenes’’ to predict the radiation status
of people and provided the basis for our current effort to develop a
rapid, high throughput biodosimetry assay for application in a
radiation mass casualty scenario.
While these studies have clearly identified PB metagenes that
can predict radiation status and dose of exposure after total body
irradiation (TBI), an important refinement to these signatures
would be incorporation of analysis of partially-exposed individuals;
this is particularly important in the development of an biodosim-
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percentage of radiation victims in a mass casualty scenario will
have heterogeneous exposures due to partial shielding [11–13].
Here, we identify PB gene expression profiles of partial body
irradiation that can predict the radiation status of partially
irradiated animals with a high degree of accuracy. We also show
that such PB signatures can potentially distinguish the anatomic
site of radiation exposure and that PB signatures generated from
TBI-treated animals fail to predict the radiation status of partially
irradiated animals. An algorithm which incorporates TBI- and
partial body-signatures can allow rapid determination of the health
of individuals in a mass casualty radiation event.
Methods
Murine irradiation study
Twelve week old female C57Bl6 mice (Jackson Laboratory, Bar
Harbor, ME) were housed at the Duke Cancer Center Isolation
Facility and all protocols in this study were approved by the Duke
University Animal Care and Use Committee (Protocol Number
A037-10-02). Six to seven mice/group were treated with partial
body irradiation to either the anterior hemibody (AH), posterior
hemibody (PH), or hind limb (HL) regions with an X-ray source at
doses of 0.5, 2, or 10 Gy using a filter of 0.1 mm Cu and 2.5 mm
Al. After dosimetry studies were performed to assess absorbed dose
in the body and in the hind limb of the animal, anterior and
posterior regions of the mice were irradiated at an average of
1.49 Gy/min and the hind limbs at an average of 1.25 Gy/min.
Six hours post-irradiation, approximately 500 ul peripheral blood
was collected by cardiac bleed from both irradiated and control
mice. PB mononuclear cells (PB MNCs) were isolated by
Lymphoprep density gradient centrifugation (Axis-Shield PoC
AS, Oslo, Norway) and total RNA was extracted with a Qiagen
RNEasy Mini Kit (Qiagen Inc., Valencia, CA) as previously
described [9,10]. RNA quality was assayed using an Agilent
Bioanalyzer 2100 (Agilent Technologies, Inc., Palo Alto, CA).
DNA Microarrays
Mouse and human oligonucleotide arrays were printed at the
Duke Microarray Facility using Operon’s Mouse Genome Oligo
sets (version 4.0). Operon’s Mouse Genome Oligo set (version 4.0)
(https://www.operon.com/arrays/oligosets_mouse.php) contains
35,852 oligonucleotide probes representing 25,000 genes and
approximately 38,000 transcripts. In comparing to previously
published total body irradiation dataset [9,10], Operon provided a
map that matched the probes from both versions and only these
were used in the analysis.
RNA and Microarray Probe Preparation and Hybridization
Briefly, MNCs were pelleted, and total RNA was isolated using
the RNeasy mini spin column as previously described [10]. Total
RNA from each sample and the universal reference RNA
(Universal Mouse Reference RNA, Stratagene, http://www.
stratagene.com) were amplified and used in probe preparation as
previously described [9]. The sample was labeled with Cy5 and
the mouse reference was labeled with Cy3. The reference RNA
allows for the signal for each gene to be normalized to its own
unique factor allowing comparisons of gene expression across
multiple samples. This serves as a normalization control for two-
color microarrays and an internal standardization for the arrays.
Amplification, probe preparation and hybridization protocols were
performed as previously described [9] and multiple replicates were
examined in each condition. Detailed protocols are available on
the Duke Microarray Facility web site (http://microarray.genome.
duke.edu/services/spotted-arrays/protocols).
Data Processing and Statistical Analysis
Genespring GX 7.3 (Agilent Technologies) was used to perform
Lowess normalization of the data and then the data was filtered in
which spots whose signal intensities below 70 in either the Cy3 or
Cy5 channel were removed. To then account for missing values,
PAM software (http://www-stat.stanford.edu/tibs/PAM/) was
used to impute missing values. k-nearest neighbor was used where
missing values were imputed using a k-nearest neighbor average in
gene space.
Gene expression profiles of dose response for anterior, posterior
and hind limb irradiation were used in three different statistical
analyses: 1) a supervised analysis using binary regression
methodologies as described previously [9,10], 2) an unsupervised
‘‘latent factor’’ analysis described in [14] and exemplified in
[15–17], and 3) a standard supervised analysis utilizing t-tests and
correction for multiple testing. The additional analyses were
performed to validate the poor performance of the supervised
binary predictor when the model was built using total body
radiation exposure and used to predict partial body radiation
exposure.
Prediction analysis of the expression data based on the supervised
binary regression analysis was performed using MATLAB software
as previously described [9]. When predicting levels of radiation
exposure, gene selection and identification is based on training the
data and finding those genes most highly correlated to radiation
exposure. Each signature summarizes its constituent genes as a
single expression profile and is here derived as the first principal
component of that set of genes (the factor corresponding to the
largest singular value), as determined by a singular value
decomposition. Given a training set of expression vectors (of values
across metagenes) representing two biological states, a binary probit
regression model is estimated using Bayesian methods. Bayesian
fitting of binary probit regression models to the training data
permits an assessment of the relevance of the metagene signatures in
sample classification. The regression models are assigned binary
regression weights which map metagenes to probabilities of
radiation exposure. To internally validate the predictive capacity
of the metagene profiles, we performed leave-one-out cross
validation studies as we have previously described [9]. A leave
one out cross validation involves removing one sample from the
dataset,usingthe remainingsamplesto develop themodel,andthen
predicting thestatusofthe held outsample.Thisis thenrepeated for
each sample in the dataset. We have utilized this approach as
previously described [9,10]. A ROC curve analysis was used to
define a cut-off for sensitivity and specificity in the predictive models
of radiation. All microarray data files will be submitted and
available at the gene expression omnibus (GEO) website.
Analysis based on unsupervised factor models was carried out
with publicly available software as previously described [18]. The
total body radiation exposure was modeled using twenty three
latent factors without regard to the radiation exposure dosage
(unsupervised). These factors were then used to build a binary
predictor of radiation exposure. Performance of this classifier on
the training data set was perfect, indicating a clear, strong response
in the peripheral blood to total body radiation exposure. These
same factors were then projected onto the data from partial body
exposure, as described in [16]. The ‘‘exposure’’ model was then
tested for performance on the partial body radiation data. Finally,
all genes were tested for association with total body and partial
body radiation exposure (ANOVA) and p-values signifying the
strength of association were generated.
Genomic Profile of Radiation
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Mice were irradiated at the doses described previously (n=2
non-irradiated; n=3 for all other doses). At 6 hours post
irradiation, PB MNCs were isolated and stained for flow
cytometry using rat anti mouse APC-Ter-119, APC-B220, PE-
Mac-1, PE-Gr-1, and FITC-Thy1.2 antibodies (Becton Dickinson,
BD). Cell subsets were analyzed as a percentage of the live cell
population. For the survival analysis, mice were irradiated with the
X-ray source at 10 Gy to either AH (n=10) or PH (n=10) as
described above. Mice were followed for 60 days post-irradiation
to assess differences in survival.
Results
PB signature of anterior hemibody (AH) irradiation
We first sought to determine if irradiation of one-half of the body
could produce a PB gene expression responsethat wascharacteristic
ofthatlevelofradiationexposureandwhetherirradiationoftheAH
(head to T12), PH (below T12) or HL (single hind limb) produced
unique PB gene expression profiles. Of note, irradiation to the AH
encompasses the spleen, whereas irradiation to the PH encompasses
the pelvis and both femurs. Twelve week old C57Bl6 female mice
(n=6–7 per group) were irradiated with single fractions of 0.5 Gy,
2 Gy or 10 Gy and PB was collected at 6 hours post-irradiation for
analysis. We chose these dose levels since they reflect medically
distinct exposure levels which require different levels of intervention
(e.g. 10 Gy is 100% lethal) [1–4,9]. In order to determine if there
was structure evident in the gene expression response to AH
irradiation, we performed a supervised binary regression analysis of
PB samples from mice irradiated with 0.5, 2, and 10 Gy AH
irradiation. A pattern of gene expression could be identified that
effectively distinguished mice irradiated to AH compared to non-
irradiated mice (Figure 1A). In order to validate that these patterns
didindeedrepresentgenesreflectingexposuretoAHirradiation,we
performed a leave-one-out cross validation analysis to assess the
ability of the pattern to predict the radiation status of unknown PB
samples. The results demonstrate that the pattern selected for
distinguishing AH-irradiated animals from non-irradiated controls
does indeed have the capacity to predict the radiation status of PB
samples from irradiated and non-irradiated mice with an accuracy
of 92%, 100% and 93% for the 0.5, 2, and 10 Gy signatures
(Figure 1A). We conclude that irradiation of the AH produces a PB
gene signature of radiation that reflects radiation status and can
potentially be used to predict radiation status.
PB signature of PH irradiation
We also irradiated a group of mice (n=7 per dose level) to the
PH and identified PB gene expression profiles for each dose level
that reflected PH irradiation (Figure 1B). A leave-one-out cross
validation analysis was performed and demonstrated that the
pattern of gene expression reflective of PH irradiation was capable
of predicting the radiation status of PH-irradiated mice versus
non-irradiated control mice with an accuracy of 93%, 93% and
79% for 0.5 Gy, 2 Gy and 10 Gy dose levels (Figure 1B).
PB signature of HL irradiation
Since we were able to identify PB signatures of radiation that
reflected AH and PH irradiation, we sought to determine if
Figure 1. Gene expression profiles that reflect partial body irradiation. At left, gene expression patterns in the peripheral blood of mice are
shown which were selected for predicting irradiation of (A) anterior hemibody (AH), (B) posterior hemibody (PH) irradiation, and (C) hind limb (HL)
irradiation versus no irradiation at 0.5 Gy (top), 2 Gy (middle) and 10 Gy exposure (bottom). Each column represents a sample from an individual
experiment, and each row represents a gene. High expression is depicted as red and low expression is depicted as blue and the range of expression is
0.06 to 210. At right, leave one-out-cross validation analyses of the classification probabilities using the binary regression model (see Methods) of
control vs. 0.5 Gy, control vs. 2 Gy, and control vs. 10 Gy are shown. Each dot represents a PB sample from an individual mouse. These analyses
demonstrate that the signatures of (A) AH irradiation for 0.5 Gy, 2 Gy and 10 Gy were highly accurate at predicting the status of AH-irradiated from
non-irradiated mice (92%, 100% and 93% accuracy for 0.5, 2, and 10 Gy, respectively), but demonstrated less accuracy in distinguishing dose levels.
(B) The signatures of PH irradiation were highly accurate at predicting radiation status versus control mice but showed less accuracy at distinguishing
radiation dose levels. (C) The signatures of HL irradiation were highly accurate at predicting radiation status versus control mice but showed less
accuracy at distinguishing radiation dose levels.
doi:10.1371/journal.pone.0011535.g001
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that could comparably predict radiation status versus non-
irradiated controls. Interestingly, we identified patterns of PB
gene expression that appeared to distinguish HL-irradiated mice
from non-irradiated control mice using a binary regression analysis
(Figure 1C). When we applied a leave-one-out cross validation
analysis, we found that the PB signature of 0.5, 2, and 10 Gy were
surprisingly accurate at predicting the radiation status of mice
irradiated to a single hind limb as compared to non-irradiated
controls (Accuracies: 93%, 93% and 86%, respectively; Figure 1C).
Taken together, these results demonstrated the sensitivity of PB
genome wide expression analysis toward detecting radiation
exposure even in the setting of a partial body exposure to less
than 25% of the body surface area.
Partial body signatures poorly discriminate dose levels
Since the health effects of radiation exposure are a direct function
of the dose level of exposure, it would be practically important for
any bioassay for radiation exposure to have the capacity to
discriminate different dose levels. In our prior studies of TBI
exposure in mice, we identified PB gene expression profiles which
were capable of discriminating dose levels of 0.5, 2, and 10 Gy TBI
[9,10]. Such discrimination is important since 0.5 Gy exposure
causes no acute health effects, whereas 2 Gy is myelosuppressive
and immunosuppressive and 10 Gy is a lethal exposure. In the
current study, we found that the gene expression profiles of AH-,
PH- and HL-irradiation were not accurate at discriminating one
dose level of irradiation from another. For example, the overall
accuracy of the AH 0.5 Gy signature at distinguishing 0.5 Gy-
irradiated samples from non-irradiated, 2 Gy-irradiated or 10 Gy-
irradiated was 54% overall (Figure 1A). Similarly, the PH 2 Gy
signature demonstrated an overall accuracy of 61% in distinguish-
ing that dose level versus the other dose levels of PH exposure
(Figure 1). None of the PB profiles within the AH, PH or HL
conditions demonstrated an accuracy greater than 60% in
distinguishing dose level (Figure 1). Consistent with these results,
we found only 6 genes in common between 0.5, 2, and 10 Gy gene
expression profiles within the AH condition: aryl hydrocarbon receptor
(AHR), neuropsin (Prss19), R-spondin, lectin-galactose binding-soluble 3
(Lgals3), NTF2-related export protein, and nuclear factor-IL3 regulated;n o
genes were in common between the 3 dose levels in the PH
condition and Pscd3 and Slc41a3 were in common at all dose levels
in the HL group (Table 1 and Table S1). Taken together, these data
indicate that partial body radiation exposure induces distinct
molecular responses in the PB as a function of dose level.
Partial body signatures are unique to the anatomic site
that is irradiated
We next sought to determine if PB signatures of partial body
irradiation were capable of predicting the status of other partially
irradiated mice in which different parts of the body had been
irradiated. The predictors of partial irradiation to AH, PH and HL
(n=25-50 genes from Figure 1) were utilized to predict radiation
status by anatomic site. Surprisingly, the PB signatures of partial
body irradiation demonstrated low accuracy in predicting the
radiation status of other mice irradiated at the same dose level to
other parts of the body (Figure 2). For example, the PB signature
of 10 Gy AH failed to predict the status of 57% and 86% the PB
samples from mice irradiated with 10 Gy to the PH or HL,
respectively. This lack of accuracy in predicting radiation status of
PB samples from partially irradiated mice was irrespective of dose
level and anatomic location; for example, the PB signature of 2 Gy
HL exposure failed to predict the radiation status of 66% and 71%
of the PB samples from mice irradiated with 2 Gy to the AH or
PH, respectively. Consistent with these results, we found little
overlap in genes represented within the AH, PH or HL radiation
groups at any dose level and only 1 gene which overlapped
between all 3 conditions (RIKEN cDNA 6330579B17) at the 10 Gy
dose level (Table S2). Taken together, these data demonstrate that
ionizing radiation induces distinct PB molecular responses as a
function of the anatomic site of exposure, rather than a redundant
molecular response based upon the percentage of body surface
area that is irradiated.
PB signatures of TBI fail to predict the status of partially
irradiated mice
Since PB signatures of radiation injury developed from TBI-
patients are currently being developed as biodosimetry assays for
Table 1. Overlap genes between 0.5, 2.0 and 10 Gy dose levels in partially irradiated mice.
Operon OligoID Gene Symbol RefSeq GenBank Description
Anterior 0.5 Gy, 2.0 Gy, and 10.0 Gy
M200001752 Ahr NM_013464 aryl-hydrocarbon receptor
M200002206 Prss19 NM_008940 D30785 protease, serine, 19 (neuropsin)
M200013923 Rspondin NM_138683 AB016768 thrombospondin type 1 domain containing
gene
M300021033 Lgals3 NM_010705 lectin, galactose binding, soluble 3
M400001965 Nxt1 NM_019761 AA915380 NTF2-related export protein 1
M400005620 Nfil3 NM_017373 nuclear factor, interleukin 3, regulated
Posterior 0.5 Gy, 2.0 Gy, and 10.0 Gy
NONE
Hind Limb 0.5 Gy, 2.0 Gy, and 10.0 Gy
M200003725 Pscd3 NM_011182 BC035296 pleckstrin homology, Sec7 and coiled-coil
domains 3
M200007299 Slc41a3 XM_132686 PREDICTED: solute carrier family 41, member 3
M400014572
doi:10.1371/journal.pone.0011535.t001
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to determine if the PB signatures generated from TBI-mice can
accurately discriminate PB samples from partially irradiated mice.
For this analysis, predictors of 0.5, 2, and 10 Gy developed from
the PB of TBI-mice were tested against PB samples from mice
exposed to 0.5, 2, or 10 Gy to AH, PH or HL. Interestingly, we
found that none of the predictors of 0.5, 2, or 10 Gy irradiation
generated from TBI-mice were able to predict the radiation status
of partially irradiated mice at the identical dose levels from the
AH, PH or HL groups (Figure 3A). Specifically, PB signatures
built from TBI-mice were unable to distinguish partially irradiated
mice from non-irradiated controls and could not discriminate dose
levels in any animals. These results demonstrate that the total body
model performs poorly in attempting to predict the radiation status
of partially irradiated animals.
As an alternative approach to compare the PB gene expression
profile from TBI versus partial body irradiation, all genes were
tested for association with total body and partial body radiation
exposure (ANOVA) and p-values signifying the strength of
association were generated (Figure 3B). In order to test for the
presence of genes that are strongly associated with radiation
exposure, we perform 8151 independent t-tests. We found that
there were 53 genes in the total body exposure group that showed
significant differential expression even after Bonferroni correction
for multiple hypotheses (P,.01/8151). In contrast, there was
nearly uniform distribution of p-values generated from the partial
body radiation, suggesting a much smaller response. This analysis
does not preclude a groups of genes, each having a small response,
from being used to build predictors, but does suggest that there are
no strong single gene predictors for this phenotype. At the same
Figure 2. Gene expression profiles of partial body irradiation poorly predict the status of mice irradiated to disparate anatomic
sites. A single variable plot is shown of the leave one out cross validation analysis performed in which the gene expression profiles of (A) AH
irradiation were utilized to predict the status of mice irradiated to PH or HL at the identical dose levels (0.5 Gy, top; 2 Gy, middle; 10 Gy, bottom). (B)
PB signatures of PH irradiation were tested against mice irradiated to AH and HL at 0.5 Gy (top), 2 Gy (middle) and 10 Gy (bottom). (C) PB signatures
of HL were tested against mice irradiated to AH and PH at 0.5 Gy (top), 2 Gy (middle) and 10 Gy (bottom). Positive prediction of radiation status is
defined by plotting of the sample above the ROC curve-defined cutoff (dotted line). Each dot represents a PB sample from an individual mouse.
doi:10.1371/journal.pone.0011535.g002
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and in addition, the smallest p-value in this group is more than an
order of magnitude too large to qualify as significant. Taken
together, these results indicate that PB signatures of radiation
generated from TBI-recipients are unlikely to accurately predict
radiation status in partially irradiated individuals.
As a corollary to the predictive analysis, we examined the genes
represented within the PB signatures of 0.5, 2, and 10 Gy TBI
versus the signatures of AH, PH and HL exposure at the same
dose levels (Table S3). We found no more than 3 genes which
overlapped between the TBI signatures and the partial body
irradiation signatures at any dose level. For example, the PB
signature of 10 Gy exposure in AH-treated mice had no genes in
common with the PB signature of 10 Gy TBI-mice and only 2
genes (Cdkn1a and Dcxr) were found to be in common between the
10 Gy TBI signature and the 10 Gy signature from PH-treated
mice (Table S3). Taken together, these results confirmed that
partial body irradiation produces a wholly distinct molecular
response in the PB compared to TBI at the same dose levels. As
complementary evidence that the biologic response to partial body
irradiation is distinct from TBI, we also found that adult C57Bl6
mice (n=10/group) irradiated with 10 Gy to AH or PH had
100% survival through 60 days (data not shown), whereas10 Gy
TBI is 100% lethal by day 30 in C57Bl6 mice [20].
PB cell content differs following TBI versus partial body
irradiation
Since partial body irradiation produced significantly different
PB gene expression profiles compared to TBI, we analyzed PB
from partially irradiated versus TBI-mice to determine if changes
in PB cell content contributed to these differences. TBI caused a
33% decrease in PB MNCs within 6 hours of exposure (Figure 4),
but partial body exposures caused an increase in PB MNCs
compared to non-irradiated mice (Figure 4). TBI caused a modest
increase in PB Mac-1
+ myeloid cells and a modest decrease in
Thy1.2
+ T cells but both populations doubled in the PB following
partial body irradiation to AH or PH. B220
+ B lymphocytes
decreased by .10-fold in the PB in response to TBI and were
predominantly not affected by partial body irradiation. Taken
together, these results suggest a model in which TBI causes a rapid
and significant shift in the proportion of circulating PB cells which
contribute to the PB gene expression profile (myeloid and T cells
.... B cells) compared to partially irradiated mice. These
Figure 3. Prediction of radiation status of partially irradiated mice based upon the TBI gene expression profiles. (A) Diamonds
represent control (non irradiated) samples, circles are exposure to AH, triangles are exposure to PH and Xs represent exposure to HL. Different dose
levels were tested (blue=non-irradiated, red=0.5 Gy, black=2 Gy, green=10 Gy). The predictor built with the TBI samples shows no capacity to
predict the radiation status of partially irradiated mice. (B) Histogram showing association of P values for association of genes with radiation
exposure. A large increase in the number of small P values close to zero is observed compared to uniform distribution in the total body irradiation
group (left). No trend is evident in P values in the partial body irradiated group of genes.
doi:10.1371/journal.pone.0011535.g003
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irradiated-mice may be explained, in part, by the generalized
mobilization of hematopoietic cell subsets which occurs following
partial body irradiation [21]. Since AH irradiation spares both
femurs and PH irradiation spares the hematopoietic spleen, it is
not surprising that mice irradiated to AH or PH would sustain PB
cell counts whereas TBI-treated mice would not. These differences
in PB cell content may also reflect the capacity for BM progenitor
cells to mobilize into the PB in response to injury at distant
anatomic sites [21,22].
Discussion
Gene expression profiles of solid tumors have been successfully
applied to predict patient prognosis and the responsiveness of
various cancers to different chemotherapies [23–26]. Peripheral
blood (PB) gene expression profiles have also been applied to
develop signatures of autoimmune diseases, stroke, bacterial and
viral infections [27–31]. An important additional application of
gene expression profiling would be to facilitate detection of
exposure to environmental hazards, such as ionizing radiation and
organic compounds (e.g. benzene). Exposure to such environmen-
tal hazards increases the longitudinal risk for hematologic diseases
as well as the development of cancer over time [32,33]. For
example, repetitive CT scans as commonly performed in the
follow up of young patients with a history of cancer, deliver
significant radiation exposure which confers an increased risk of
cancer development over time [34]. Similarly, repetitive occupa-
tional exposure to radiation, as occurs amongst interventional
cardiologists and radiology technicians, may increase the lifetime
Figure 4. Partial body irradiation and TBI cause significantly different changes in PB cell distributions. (A) The mean numbers of PB
MNCs are shown in non-irradiated (untreated) mice versus mice irradiated with TBI, AH, PH or HL irradiation. *P=0.02 for comparison with non-
irradiated mice; ‘ P=0.007, ‘‘P=0.004, ‘‘‘P=0.02 for comparison with non-irradiated mice;
#P=0.03,
##P=0.03,




DDDP=0.004 for comparison with non-irradiated mice. (B) TBI causes a significant decrease in PB B cells
(B220
+) at increasing dose levels. *P=0.04, **P=0.03; AH and PH irradiation decrease PB B cells at 10 Gy, ‘P=0.03; HL irradiation increases PB B cell
content at all doses,
#P=0.003. (C) TBI causes a modest decrease in PB T cells (Thy 1.2
+) at 10 Gy; AH, PH and HL irradiation uniformly cause an
increase in PB T cells compared to non-irradiated controls, *P=0.01, **P=0.04,
#P=0.01, ‘P=0.01, ‘‘P=0.04, ‘‘‘P=0.01. (D) TBI causes no significant
change in PB myeloid (Mac-1
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of absorbed radiation dose (biodosimetry) or quantify the risk of
such radiation exposure toward the development of cancer. Such
concerns are magnified when considered in the context of the
current well-articulated objective of terrorists to use radiological or
improvised nuclear weapons to attack the United States; in the
latter scenario, detonation of a ‘‘dirty bomb’’ or improvised
nuclear device (IND) in a U.S. city could cause radiation injury to
hundreds of thousands of individuals at one time.
We have sought to develop a PB assay for ionizing radiation
exposure using gene expression profiles. Recently, we demonstrated
that PB signatures of TBI exposure were capable of predicting both
radiation status and dose level of exposure in mice with 96%
accuracy [9]. We subsequently showed that a PB signature of as few
as 25 genes developed in human patients exposed to TBI was
capable of predicting the radiation status of irradiated and healthy
individuals with an overall accuracy of 94% [10]. However, in the
event of a radiological or nuclear detonation, it canbe expected that
a large percentage of exposed victims will have heterogeneous
radiation exposure as a function of partial shielding [11–13];
therefore, PB signatures of TBI may not be predictive or applicable
to diagnose radiation exposure in people who have suffered only
partial body irradiation. Here, we found that irradiation of 50% of
the body surface area (anterior or posterior) in mice with 0.5–10 Gy
produced PB patterns of gene expression that were characteristic of
these exposures. Interestingly, radiation exposure to a single hind
limb also produced characteristic PB signatures in mice, suggesting
that genome-wide analysis of the PB is quite sensitive to detect
radiation exposure to a relatively small portion of the body surface
area. We also demonstrate that such PB signatures of partial body
irradiation arecapable ofpredictingtheradiationstatusofunknown
PB samples from mice with an accuracy of 79–100%. However, the
PB signatures of hemi-body or single limb irradiation were
incapable of distinguishing the dose level of exposure between 0.5,
2, and 10 Gy. This is in sharp contrast to our prior observation that
TBI exposure produced PB signatures of 0.5, 2, and 10 Gy which
were highly accurate (96%) at predicting the dose level of exposure
in mice [9]. We also found few genes in common between the
predictors of 0.5, 2, or 10 Gy within any of the partial body
irradiation conditions. One possible explanation for the inability of
partial body irradiation signatures to discriminate dose levels
accurately is that partial body irradiation produces a weaker
molecularsignalinthePBcompared toTBI.Itislikelythatthegene
expression profile of irradiation is muted in partially irradiated mice
by the contribution of circulating, non-irradiated hematopoietic
cells.
Despite the fact that we were able to identify PB signatures of
partial body exposure that predicted radiation status within the
AH, PH and HL exposure groups, we also found that the PB
signatures of partial body irradiation failed to predict radiation
status based upon site of exposure. For example, the PB signature
of 2 Gy AH irradiation failed to predict the radiation status of
mice treated with 2 Gy to PH. Similarly, the PB signature of
10 Gy PH failed to predict the radiation status of mice irradiated
with 10 Gy to HL. Taken together, these results suggested that the
PB molecular response to ionizing radiation is distinct depending
upon which portion of the body is exposed. Examination of the
genes which comprise the PB signatures of partial body irradiation
provide a possible explanation for the lack of predictions across
different partial irradiation conditions. We found no overlapping
genes between the 3 partial body irradiation conditions at 0.5 or
2 Gy dose levels and only 1 non-annotated gene, RIKEN cDNA
6330579B17, which was in common between the AH, PH and HL
groups at 10 Gy dose level. Taken in a broader context, these
results demonstrate that partial body irradiation induces unique
PB molecular responses as a function of the extent of the exposure
and that caution should be applied when applying PB gene
signatures to diagnose partially irradiated individuals. Further-
more, the lack of ability to discriminate dose levels across different
partial body conditions suggests that distinct reference gene
expression profiles may be necessary to accurately predict the
radiation status of partially irradiated individuals.
Recently, we and others have sought to develop and validate PB
signatures of radiation exposure generated from TBI treatment of
mice and/or humans for the purpose of biodosimetry in a mass
casualty radiation event [9,10,19]. These studies have generated
optimism that PB gene expression profiles could be applied in a
high throughput fashion as a means of screening or triaging
thousands of individuals following a dirty bomb or IND
detonation in a large city [9,10,37,38]. Interestingly, independent
studies have confirmed the potential accuracy of gene expression
profiling to predict radiation status using ex vivo irradiated human
PB samples [37] and instruments are currently under development
to apply such signatures in the analysis of small blood volumes
[39]. Other strategies which have shown promise in biodosimetry
include qRT-PCR analysis of specific PB biomarkers (e.g.
GADD45)[40], ELISA of multiple blood proteins [41] and urinary
metabolomics which utilizes ultra-performance liquid chromatog-
raphy-time of flight mass spectrometry (UPLC-TOFMS) [42].
However, we show here that PB signatures generated from TBI-
treated mice or humans may not be able to predict the radiation
status of partially irradiated people or predict the dose level of
radiation exposure in such individuals. Similarly, we found very
few genes in common between the PB signatures of partial body
irradiation and our previously developed PB signatures of TBI
(Table S3) and found only 1 gene, Cdkn1a, in common with a PB
signature of human TBI exposure [19]. The divergent hemato-
logic consequences of partial body irradiation and TBI were also
evident in the PB cell content, which revealed substantial depletion
of total PB MNCs and B cells in the TBI-treated mice compared to
partially irradiated mice. Nevertheless, it is also clear that there is
the potential to develop signatures that can accurately predict the
partial body radiation events, including the anatomic location of
the radiation. While we might have hoped that a simple assay
could be used independent of the nature of the radiation exposure,
it still could be feasible to employ a collection of signatures as the
basis for an assay that assessed the nature and extent of a radiation
exposure. In reality, the use of multiple signatures does not make
the actual assay more difficult since it is one measure of the full
complement of genes that is made and then the activity of the
various signatures is measured from this gene expression data. As
such, it should be possible to develop an algorithm that evaluated
each of the relevant signatures (total body, partial body by site) to
then make a determination of the health status of the individual.
In a broader context, the PB radiation signatures that we have
developed have the potential to serve as biomarkers of individual
susceptibility to radiation-induced toxicity in patients undergoing
large volume therapeutic irradiation or TBI. Moreover, sufficient
molecular overlap has now been established between normal
hematopoietic stem cells and cancer stem cells [43] such that the
PB signatures of radiation sensitivity developed here may help to
predict the susceptibility of certain cancers to radiation therapy.
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